John Reed, J&J’s EVP of innovative medicine

J&J promis­es 20 new drugs to back phar­ma growth through end of decade, as John Reed shares his plans

John­son & John­son is lay­ing out its drug de­vel­op­ment am­bi­tions un­der its new R&D chief, pro­ject­ing that it will bring in bil­lions of dol­lars in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.